970*90
768
468
mobile

Regeneron backs bluebird with $100 mn, jointly work on cancer therapies

Franchise India Bureau
Franchise India Bureau Aug 06 2018 - 1 min read
Regeneron backs bluebird with $100 mn, jointly work on cancer therapies
The investment will be at $238.10 per share, a premium of nearly 59 percent over bluebird's Friday closing price.

Regeneron Pharmaceuticals Inc has announced to invest $100 million in cancer drug developer bluebird bio Inc, and jointly the companies will develop new cell therapies for cancer.

The investment will be at $238.10 per share, a premium of nearly 59 percent over bluebird's Friday closing price.

Bluebird bio's shares were up about 7 pct at $160.50 in premarket trading on Monday.

The companies will use Regeneron's VelociSuite platform technologies for the discovery of human antibodies as well as T cell receptors and bluebird's gene transfer techniques.

Bluebird's technology is more into the emerging class of treatments known as CAR-T therapy, which involves genetic manipulation of a patient's immune system.

The companies have selected six initial targets and will equally share the costs of research and development up to the point of submitting a marketing application in the United States.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online